The nation of Zimbabwe has declined a substantial US health deal worth $367m (£272m) over five years over Washington's insistence on confidential information.
The decision became public after a internal memorandum from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government representative has since clarified that the US was requesting genetic material for scientific study and commercial purposes but refused to share the resulting advantages from any future vaccines.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for more talks to find a deal acceptable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Implications
This rejection follows a comparable case in Kenya, where a court halted a related deal with the US after concerns were filed about the safety of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had administered assistance for the American government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government deals to boost openness and accountability.
As per reports, 16 African countries have so far agreed to these new agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to surrender its biological resources and data for a long time, with no corresponding assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," his statement read.
"Effectively, our nation would supply the raw materials for scientific discovery without any assurance that the final treatments would be available to our population should a new health crisis arise."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were disrupting structures already established through the global organization.
Mangwana cited its Pandemic Benefit-Sharing framework created to manage future pandemics.
"This system is designed to guarantee that when a country provides its information, the benefits – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our American counterparts on how future co-operation could be structured in a way that respects the independence and interests of each country."
Medical Community Reaction
A leading public health body expressed it recognised the government's concerns, but urged that talks should continue considering a large portion of the nation's HIV programmes were funded by foreign aid.
"If technical issues exist, including those relating to data governance or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," it added.
This impasse emphasises the continuing tensions between accepting crucial international aid and protecting local interests in an ever more interconnected world.